Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p28 is a synthetic, 28-amino acid peptide derived from the bacterial protein azurin. It functions as a cell-penetrating peptide with anticancer properties. The mechanism of action involves selective entry into cancer cells, where it binds to and stabilizes the tumor suppressor protein p53, leading to increased apoptosis and inhibition of tumor growth. Preclinical studies have shown that p28 can induce cancer cell death without significant toxicity to normal cells. It has been investigated primarily for use in solid tumors and recurrent or refractory pediatric brain tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on p28.